Royalty Pharma Plc
RPRXRoyalty Pharma is a biopharmaceutical company based in New York City that purchases economic interests in marketed and late stage biopharmaceutical products from life sciences organizations. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with …
© Wikipedia /
Creative Commons CC-BY-SA 3.0
more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Royalty Pharma Plc
Subscribe RSS| Date | Type | Ø-Price | Volume |
|---|---|---|---|
| 7/1/2026 | Sell | $55.9 | $508,454 |
| 6/30/2026 | Sell | $56.8 | $7,345,471 |
| 6/24/2026 | Sell | $55.2 | $502,067 |
| 6/23/2026 | Sell | $54.3 | $8,159,277 |
| 5/26/2026 | Sell | $54.0 | $3,476,116 |
| 5/20/2026 | Sell | $52.8 | $721,838 |
| 5/14/2026 | Sell | $53.0 | $161,385 |
| 5/14/2026 | Sell | $53.1 | $726,137 |
| 4/28/2026 | Sell | $49.8 | $1,731,841 |
| 4/1/2026 | Sell | $48.3 | $1,681,512 |
| 3/23/2026 | Sell | $45.5 | $1,583,989 |
| 3/2/2026 | Sell | $46.8 | $1,627,534 |
| 2/23/2026 | Sell | $45.3 | $1,576,606 |
| 2/4/2026 | Sell | $43.3 | $872,912 |
| 2/3/2026 | Sell | $42.8 | $4,924,997 |
| 2/2/2026 | Sell | $42.1 | $4,562,905 |
| 1/30/2026 | Sell | $41.1 | $821,810 |
| 1/23/2026 | Sell | $40.3 | $805,110 |
| 1/20/2026 | Sell | $39.4 | $2,737,941 |
| 1/16/2026 | Sell | $39.5 | $790,346 |
| 1/9/2026 | Sell | $40.8 | $815,634 |
| 1/2/2026 | Sell | $38.4 | $2,673,041 |
| 1/2/2026 | Sell | $38.5 | $769,650 |
| 12/26/2025 | Sell | $39.3 | $786,380 |
| 12/19/2025 | Sell | $38.4 | $767,582 |
| 12/18/2025 | Sell | $38.5 | $1,180,053 |
| 12/17/2025 | Sell | $38.6 | $3,060,280 |
| 12/16/2025 | Sell | $38.3 | $766,420 |
| 12/15/2025 | Sell | $38.4 | $2,669,172 |
| 12/5/2025 | Sell | $39.2 | $1,627,815 |
| 12/3/2025 | Sell | $39.8 | $4,375,008 |
| 12/1/2025 | Sell | $39.9 | $2,773,957 |
| 12/1/2025 | Sell | $39.9 | $1,659,489 |
| 11/24/2025 | Sell | $38.3 | $2,682,506 |
| 11/19/2025 | Sell | $38.6 | $5,192,658 |
| 11/17/2025 | Sell | $39.3 | $2,735,329 |
| 8/11/2025 | Sell | $36.2 | $1,213,749 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)